Precise manufacturing of PoC Rapid Tests
In the dynamic landscape of healthcare, the need for fast and accurate diagnostic tools has never been greater. As the world grapples with various health challenges, from infectious diseases to chronic conditions, the ability to quickly detect and respond to these threats is paramount. One of the most important aspects of this response is the production of rapid Point of Care (PoC) tests. Point-of-care tests are used daily for many different symptoms and are the standard for rapid diagnosis. The arbitrary formats of microfluidic test substrates require flexible and precise solutions for the pre-storage of test reagents.
Quality Control with TOPVIEW feature
The TOPVIEW camera is distinguished by its exceptional image quality and precision, making it an invaluable tool for detailed inspections of dispensed droplets. It meticulously monitors each dispense to ensure accurate placement on the designated substrate. Equipped with high-resolution optics and advanced image processing technology, the TopView camera is capable of detecting even the most minute deviations that could compromise the accuracy and integrity of the test. This ensures that every dispense is precisely positioned, maintaining the highest standards of accuracy and reliability in your experiments.
Consitency and reproducibility
The TOPVIEW camera, with its exceptional image quality and precision, is invaluable for inspecting dispensed droplets. It ensures accurate placement on substrates, detecting even minute deviations to maintain test accuracy and reliability.
Leverage piezoelectric drop-on-demand dispensing for nanoliter droplet volumes, providing flexibility in development and robust performance in mass production. Enjoy freedom in designing array layouts and benefit from a reliable dispensing mechanism. Our piezoelectric technology ensures precision, versatility, and consistency, enhancing innovation and scalability in your projects.
Scalability
The BIOSPOT® system is ideal for use in diagnostics and at the point-of-care, offering scalable liquid handling that ensures precise and reliable dispensing for rapid test development. Its flexible integration and ability to seamlessly transition from R&D to production make it ideal for increasing throughput in diagnostic laboratories without compromising accuracy, facilitating rapid responses to healthcare needs.
With its ease of use and specific individuality, our workstation is the ideal machine to produce any type of PoC rapid test.
Premier Solution for Accurate PoC-Rapid Test Manufacturing: BIOSPOT® workstation
Cutting-Edge features of BIOSPOT®
Automated Volume Calibration | SmartDrop: Ensures precise and reliable volume measurements every time.
Integrated Process Control | TopView: Provides seamless monitoring and control for optimized workflows.
Unmatched Precision: Achieve accuracy with increments of less than 10 µm.
Dynamic Volume Range: Capable of handling volumes from picoliters to microliters, adapting to your needs.
Fiducial Alignment | Substrate Recognition: Enhances accuracy and repeatability by recognizing and aligning substrates automatically.
Any substrate - Any position - Any liquid
Discover the ultimate solution for Point of Care (PoC) rapid test manufacturing with our BIOSPOT® workstation. Engineered for unparalleled versatility, it excels in dispensing on any substrate independent on the liquid type. Whether it's microfluidic test substrates or other formats, our workstation ensures seamless and precise dispensing, making it the perfect fit for PoC rapid test manufacturing. Experience the power of flexibility and reliability in your diagnostic processes with BIOSPOT®.
Our BIOSPOT® DX workstation automates your production with incredible precision and accuracy.
Accuracy and Sensitivity
The BIOSPOT® workstation is designed to revolutionize PoC-Rapid Test manufacturing with unparalleled accuracy and sensitivity. Utilizing cutting-edge technology, BIOSPOT® ensures precise dispensing and processing, significantly reducing variability and enhancing test reliability. Its advanced features enable the detection of minute biological markers, providing highly sensitive results essential for accurate diagnostics. With BIOSPOT®, you achieve consistent, high-quality outcomes in every test.
Adjust the line width
Tailor your dispensed lines with precision by setting droplet volumes using the SMARTDROP® System.
Achieve precise line thickness with customizable droplet volumes. Smaller droplet volumes reduce line thickness, providing exact specifications for your substrate. Experience enhanced control and accuracy, ensuring your lines meet the desired thickness with efficiency.
Relevant literature
Lateral flow assays (LFAs) are widely used for rapid diagnostic testing and initial screening. A one-step and low-cost analysis of an analyte in a sample solution, such as pathogens, biomarkers and chemical contaminants, makes it a powerful point-of-care device without the need of trained personnel. Read how to optimize, develop and to produce LFA applying Hamilton Freiburg technology.
Nanomaterials have been widely reported in lateral flow biosensors, offering new sensing strategies based on optical or electrical detection techniques. Looking for other advantageous nanomaterials, we propose for the first time the use of iridium oxide (IV) nanoparticles in lateral flow assays for the detection of human immunoglobulin as a model protein.
Lateral flow paper-based biosensors merge as powerful tools in point-of-care diagnostics since they are cheap, portable, robust, selective, fast and easy to use. However, the sensitivity of this type of biosensors is not always as high as required, often not permitting a clear quantification. To improve the colorimetric response of standard lateral flow strips (LFs), we have applied a new enhancement strategy that increases the sensitivity of LFs based on the use of cellulose nanofibers (CNF). CNF penetrate inside the pores of LFs nitrocellulose paper, compacting the pore size only in the test line, particularly near the surface of the strip. This modification retains the bioreceptors (antibodies) close to the surface of the strips, and thus further increasing the density of selectively attached gold nanoparticles (AuNPs) in the top part of the membrane, in the test line area, only when the sample is positive.
Lateral flow strips (LFSs) are widely used for clinical diagnostics. The restricted flow control of the current designs is one challenge to the development of quantitative and highly sensitive LFSs. Here, we present a flow control for LFSs using centrifugal microfluidics. In contrast to previously presented implementations of lateral flow membranes into centrifugal microfluidic cartridges, we direct the flow radially outwards through the membrane. We control the flow using only the centrifugal force, thus it is independent of membrane wetting properties and permeability. The flow rate can be decreased and increased, enabling control of incubation times for a wide variety of samples.
The contamination in groundwater due to the presence of uranium is nowadays a subject of concern due to the severe health problems associated with renal failure, genotoxicity and cancer. [...] For the first time, we propose a portable, fast, inexpensive and sensitive paper-based biosensor able to detect in situ U(VI) in water samples: U(VI) selective gold nanoparticle-based lateral flow strips. Antibody-coated gold nanoparticles are used as labels in the proposed lateral flow system because of their biocompatibility; in addition, these nanoparticles provide high sensitivity due to their intense plasmonic effect.
The assay is intended for the detection of a model protein in human serum, that is, human immunoglobulin G, with the aim to demonstrate a virtually universal protein detection platform. Once the sample is added in the strip, the analyte is selectively captured by antibody-decorated silica beads (Ab-SiO2) onto the conjugate pad and the sample flows by capillarity throughout the strip until reaching the test line, where a sandwich-like immunocomplex takes place due to the presence of antibody-functionalized QDs (Ab-QDs) onto the test line.